Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer

Annals of Surgery

Volumn 250, Issue 2, 2009, Pages 268-272

  Ishizuka, Mitsuru ^a   Nagata, Hitoshi ^a   Takagi, Kazutoshi ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CAMPTOTHECIN; DRUG DERIVATIVE; FOLFOX PROTOCOL; IFL PROTOCOL; PLATINUM COMPLEX; SERUM ALBUMIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COLORECTAL CANCER; DIABETES MELLITUS; FAR ADVANCED OR RECURRENT UNRESECTABLE COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KAPLAN MEIER METHOD; KIDNEY DISEASE; LABORATORY TEST; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; MULTIVARIATE ANALYSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK FACTOR; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNIVARIATE ANALYSIS; COHORT ANALYSIS; COLORECTAL TUMOR; HEALTH SURVEY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CA-19-9 ANTIGEN; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEALTH STATUS INDICATORS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 68949110437     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b16e24     Document Type: Article

References (34)

1. Bouzid K, Khalfallah S, Tujakowski J, et al. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol. 2003;14:1106-1114.
2. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25:1247-1254.
3. Nordlinger B, Guiguet M, Vaillant P, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
4. Aldrighetti L, Castoldi R, Di Palo S, et al. Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases -in Italian-. Chir Ital. 2005;57:555-570.
5. McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64-69.
6. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215-219.
7. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23:263-266.
8. Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248-252. (Pubitemid 36936011)
9. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585-590. (Pubitemid 38500312)
10. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus. 2005;18:146-150.
11. Gerhardt T, Milz S, Schepke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12: 5495-5500.
12. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005;92:651-654.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
14. Forrest LM, McMillan DC, McArdle CS, et al. Comparison of an inflamma-tion-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90:1704-1706.
15. Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005; 92:1834-1836.
16. Elahi MM, McMillan DC, McArdle CS, et al. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer. 2004;48:171-173.
17. Brown DJ, Milroy R, Preston T, et al. The relationship between an inflam-mation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol. 2006;60:705-708.
18. Crumley AB, McMillan DC, McKernan M, et al. Evaluation of an inflam-mation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637-641.
19. Glen P, Jamieson NB, McMillan DC, et al. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006;6:450-453.
20. Read JA, Choy ST, Beale PJ, et al. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer. 2006;55:78-85.
21. Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109:205-212.
22. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266-1270.
23. Leung EY, Crozier JE, Talwar D, et al. Vitamin antioxidants, lipid peroxi-dation, tumour stage, the systemic inflammatory response and survival in patients with colorectal cancer. Int J Cancer. 2008;123:2460-2464.
24. Crozier JE, Leitch EF, McKee RF, et al. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg. 2009;197:544-549.
25. Al Murri AM, Bartlett JM, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94:227-230.
26. Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047-1051.
27. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881-886.
28. Dixon MR, Haukoos JS, Udani SM, et al. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg. 2003;138:962-966.
29. Wang JY, Lu CY, Chu KS, et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colo-rectal cancer. Eur Surg Res. 2007;39:245-250.
30. Reiter W, Stieber P, Reuter C, et al. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res. 1997;17:2935-2938. (Pubitemid 27434824)
31. Reiter W, Stieber P, Reuter C, et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20:5195-5198.
32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
33. Al-Shaiba R, McMillan DC, Angerson WJ, et al. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004;91:205-207.
34. Crumley AB, Stuart RC, Mc Kernan M, et al. Comparison of an inflamma-tion-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2008;23:e325-e329.